Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market

The Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market is estimated to be valued at USD 2.55 Bn in 2026 and is expected to reach USD 3.37 Bn by 2033, exhibiting a compound annual growth rate (CAGR) of 4.1% from 2026 to 2033. The market is witnessing steady growth mainly driven by the rising prevalence of chronic pancreatitis and other pancreatic disorders, increasing diagnosis and treatment of EPI, growing adoption of pancreatic enzyme replacement therapy (PERT), and rising awareness regarding EPI-associated malabsorption and nutritional deficiencies. Exocrine pancreatic insufficiency is characterized by inadequate production or delivery of pancreatic digestive enzymes, resulting in impaired digestion and nutrient absorption. The condition is commonly associated with chronic pancreatitis, cystic fibrosis, pancreatic cancer, acute pancreatitis, pancreatic surgery, and other gastrointestinal or pancreatic disorders. Treatment primarily involves pancreatic enzyme replacement therapy, supported by nutritional management and dietary modification to improve digestion, nutrient absorption, and nutritional status. Healthcare providers are increasingly focusing on early diagnosis, optimized enzyme dosing, nutritional monitoring, and treatment adherence to improve outcomes among patients with EPI. Advances in clinical management are also encouraging more personalized PERT dosing based on meal size, fat intake, disease severity, symptoms, and nutritional response. In addition, the development of next-generation recombinant oral enzyme replacement therapies is expected to expand future treatment options and potentially reduce limitations associated with conventional porcine-derived pancreatic enzyme products. Market Dynamics The market is witnessing steady momentum owing to the rising burden of chronic pancreatitis, cystic fibrosis, pancreatic cancer, and other conditions associated with pancreatic exocrine dysfunction. The growing diagnosed patient population is increasing the requirement for long-term pancreatic enzyme supplementation, particularly among patients experiencing maldigestion, malabsorption, weight loss, and nutritional deficiencies. Increasing clinical recognition and adoption of pancreatic enzyme replacement therapy is a major factor supporting market growth. PERT remains the principal therapeutic approach for EPI and is widely used to restore digestive enzyme activity and improve nutrient absorption. Increasing physician awareness, improved clinical guidelines, and greater emphasis on appropriate enzyme dosing are further strengthening treatment utilization. The market is also benefiting from improvements in gastroenterology infrastructure and increasing access to prescription enzyme therapies. Pharmaceutical companies, gastroenterologists, pancreatologists, nutrition specialists, hospital pharmacists, and specialty pharmacies play an important role in supporting diagnosis, treatment initiation, dosing optimization, and long-term management of EPI. At the same time, underdiagnosis, delayed diagnosis, and the high cost of long-term pancreatic enzyme replacement therapy remain key challenges. However, improving disease awareness, expanding treatment access, patient-support initiatives, and development of next-generation recombinant enzyme therapies are expected to support market expansion during the forecast period. Key Features of the Study • This report provides in-depth analysis of the Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players • It profiles key players in the Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies • Key companies covered as a part of this study include AbbVie, Inc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., Anthera Pharmaceuticals, Inc., Allergan plc, AzurRx BioPharma, Inc. • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics • The Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Market Segmentation • By Disease Management (Revenue, USD Bn, 2021-2033) o Nutritional Management o Pancreatic Enzyme Replacement Therapy (PERT) • By Therapeutic Drugs (Revenue, USD Bn, 2021-2033) o Creon o Zenpep o Pancreaze o Ultresa o Viokace o Others • By Region (Revenue, USD Bn, 2021-2033) o North America  U.S.  Canada o Latin America  Brazil  Mexico  Argentina  Rest of Latin America o Europe  Germany  U.K.  France  Italy  Spain  Russia  Rest of Europe o Asia Pacific  China  India  Japan  Australia  South Korea  ASEAN  Rest of Asia Pacific o Middle East  GCC  Israel  Rest of Middle East o Africa  South Africa  Central Africa  North Africa • Key Players o AbbVie, Inc. o Digestive Care, Inc. o Janssen Pharmaceuticals, Inc. o Anthera Pharmaceuticals, Inc. o Allergan plc o AzurRx BioPharma, Inc.